Methamphetamine* [Desoxyephedrine]

This chapter describes trade name, classification, approved indications for psychological disorders, usual dosage and administration, relative contraindications, clinically significant drug interactions, adverse drug reactions and overdosage of Methamphetamine. Decrements in predicted growth have been associated with long-term methamphetamine pharmacotherapy among children. Monitor height and weight closely among children who require long-term methamphetamine pharmacotherapy. Short-term adjunctive methamphetamine pharmacotherapy may be of limited benefit as a component in a medically monitored weight reduction program based on caloric restriction and exercise for patients whose obesity is refractory to alternative therapies. The mechanism of action of methamphetamine in relation to producing beneficial behavioral changes among children who have A-D/HD is unknown. Methamphetamine has been associated with problematic patterns of use since its synthesis. Reportedly, patients have increased their dosages to many times the usual recommended dosage. Methamphetamine overdosage requires emergency symptomatic medical support of body systems with attention to increasing methamphetamine elimination.